According to the website of the State Food and Drug Administration (SFDA), the Class 5 new drug under chemical medicine with independent IPR, Mesalazine Slow Release Tablets from Chongqing Pharmaceutical Research Institute Co., Ltd was approved for clinical trial by SFDA,.

It was learned that Mesalazine Slow Release Tablets are a kind of colon-specific prolonged release that can alleviate colonic mucosal inflammation through suppressing the activity of platelet activating factor and oxidation of colonic mucosa fatty acid, mainly applied to induced remission of mild and moderate active ulcerative colitis and maintenance treatment. Once-a-day Mesalazine sustained release is unavailable yet in the country. Compared with the common releases currently launched, Mesalazine Slow Release Tablets can effectively increase medication compliance, as the dose is decreased from three times a day to once a day. Meanwhile, the drug is only released to the part of colon, which reduces release and adsorption to other parts to ensure better treatment for ulcerative colitis and greater safety.